SIRPant Immunotherapeutics Inc.

SIRPant Immunotherapeutics Inc. is focused on the development of novel autologous macrophage cell therapy for solid tumors. The company believes its proprietary technologies for empowering patient innate and adaptive immune responses against cancer will play a leading role in the successful treatment of solid tumors. Initially, SIRPant is focusing on solid tumors of unmet need including head & neck, cutaneous T-cell lymphoma, colon, lung, and pancreatic cancer. SIRPant has been incorporated as a Delaware C Corporation registered to do business in Pennsylvania. The company is headquartered in the Hershey Center for Applied Research Business Campus and raised a $27M Series A in 2021. An IND will be filed Q1 2023 and first in man studies will initiate in H2, 2023. The company is initiating outreach for a Series B targeted for H2 2023 to fund clinical trials in two indications.